Letter from the Editor

Dear Colleagues,

Thank you for your interest in this summary report for the 2021 European Heart Rhythm Association Virtual Meeting. Our hope is that you find the summaries enclosed to be informative and balanced but also succinct. Our editorial team and peer reviewers have worked hard to bring you some of the very best content of the meeting.

There are important new data on atrial fibrillation including the long-term results from RACE 3 and the results of STROKESTOP. A summary of the 2021 EHRA practical guide to DOACs in the pre-operative setting and management in the context of bleeding may be helpful in the management of these situations. In addition, there are data on ablation, devices, and diagnostic tools. Finally, there are key topics regarding antiarrhythmic drugs in children and imaging for patients with congenital heart disease.

We found the meeting to be rich, engaging, and informative and we hope the following summaries accurately represent this dynamic meeting.

Sincerely,

Marc Bonaca



 

Biography

Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi

 



Posted on 16 June 20219 July 2021